UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 176

Sortiert nach

BPS804 Anti‐Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial

Journal of bone and mineral research, 2017-07, Vol.32 (7), p.1496-1504

2017

Volltextzugriff (PDF)

Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Calcified Tissue International, 2016, Vol.98 (1), p.1-17

2016

Volltextzugriff (PDF)

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

The Lancet (British edition), 2009-04, Vol.373 (9671), p.1253-1263

2009

Volltextzugriff (PDF)

Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice

Calcified tissue international, 2020-05, Vol.106 (5), p.494-508

2020

Volltextzugriff (PDF)

Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort

Journal of bone and mineral research, 2020-07, Vol.35 (7), p.1246-1252

2020

Volltextzugriff (PDF)

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2013-10, Vol.382 (9902), p.1424-1432

2013

Volltextzugriff (PDF)

A Panel-Based Sequencing Analysis of Patients with Paget’s Disease of Bone Suggests Enrichment of Rare Genetic Variation in regulators of NF-κB Signaling and Supports the Importance of the 7q33 Locus

Calcified tissue international, 2021-12, Vol.109 (6), p.656-665

2021

Volltextzugriff (PDF)

Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta

Bone (New York, N.Y.), 2019-07, Vol.124, p.137-147

2019

Volltextzugriff (PDF)

Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse

Frontiers in genetics, 2021-08, Vol.12, p.705505-705505

2021

Volltextzugriff (PDF)

Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial

Journal of bone and mineral research, 2000-06, Vol.15 (6), p.1006-1013

2000

Volltextzugriff (PDF)

Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture

Archives of osteoporosis, 2016-12, Vol.11 (1), p.37-37, Article 37

2016

Volltextzugriff (PDF)

Strontium Ranelate Reduces the Risk of Vertebral Fractures in Patients With Osteopenia

Journal of bone and mineral research, 2008-03, Vol.23 (3), p.433-438

2008

Volltextzugriff (PDF)

Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate

Journal of bone and mineral research, 2007-01, Vol.22 (1), p.142-148

2007

Volltextzugriff (PDF)

Novel LRP5 Missense Mutation in a Patient With a High Bone Mass Phenotype Results in Decreased DKK1‐Mediated Inhibition of Wnt Signaling

Journal of bone and mineral research, 2007-05, Vol.22 (5), p.708-716

2007

Volltextzugriff (PDF)

Effects of Calcitonin on Subchondral Trabecular Bone Changes and on Osteoarthritic Cartilage Lesions After Acute Anterior Cruciate Ligament Deficiency

Journal of bone and mineral research, 2004-11, Vol.19 (11), p.1821-1826

2004

Volltextzugriff (PDF)

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis : a consensus document of the Belgian Bone Club

Osteoporosis international, 2006-01, Vol.17 (1), p.8-19

2006

Volltextzugriff (PDF)

Renal expression of parvalbumin is critical for NaCl handling and response to diuretics

Proceedings of the National Academy of Sciences - PNAS, 2007-09, Vol.104 (37), p.14849-14854

2007

Volltextzugriff (PDF)

majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes

Human genetics, 2010-12, Vol.128 (6), p.615-626

2010

Volltextzugriff (PDF)

Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss

Clinical journal of the American Society of Nephrology, 2010-10, Vol.5 (10), p.1887-1892

2010

Volltextzugriff (PDF)

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

Journal of rheumatology, 2010-01, Vol.37 (1), p.141

2010

Volltextzugriff (PDF)

Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach

Rheumatic diseases clinics of North America, 2006-11, Vol.32 (4), p.733-757

Devogelaer, Jean-Pierre

2006

Volltextzugriff (PDF)

Genetic Screening of ZNF687 and PFN1 in a Paget’s Disease of Bone Cohort Indicates an Important Role for the Nuclear Localization Signal of ZNF687

Calcified tissue international, 2023-11, Vol.113 (5), p.552-557

2023

Volltextzugriff (PDF)

Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone

Journal of bone and mineral research, 2010-12, Vol.25 (12), p.2592-2605

2010

Volltextzugriff (PDF)

Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology‐Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3‐Month Effects on Biomarkers of Bone Turnover

Journal of bone and mineral research, 2004-09, Vol.19 (9), p.1531-1538

2004

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(147)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(105)
Science & Technology
(102)
Life Sciences & Biomedicine
(100)
Female
(69)
Human Health Sciences
(62)
Sciences De La Santé Humaine
(62)
General & Internal Medicine
(61)
Male
(50)
Middle Aged
(49)
Biological And Medical Sciences
(47)
Médecine Générale & Interne
(46)
Aged
(43)
Medical Sciences
(40)
Rheumatology
(38)
Endocrinology & Metabolism
(37)
Osteoporosis
(35)
Public Health, Health Care Sciences & Services
(32)
Santé Publique, Services Médicaux & Soins De Santé
(32)
Bone Density - Drug Effects
(28)
Adult
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BPS804 Anti‐Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial

Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice

Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

A Panel-Based Sequencing Analysis of Patients with Paget’s Disease of Bone Suggests Enrichment of Rare Genetic Variation in regulators of NF-κB Signaling and Supports the Importance of the 7q33 Locus

Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta

Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse

Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial

Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture

Strontium Ranelate Reduces the Risk of Vertebral Fractures in Patients With Osteopenia

Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate

Novel LRP5 Missense Mutation in a Patient With a High Bone Mass Phenotype Results in Decreased DKK1‐Mediated Inhibition of Wnt Signaling

Effects of Calcitonin on Subchondral Trabecular Bone Changes and on Osteoarthritic Cartilage Lesions After Acute Anterior Cruciate Ligament Deficiency

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis : a consensus document of the Belgian Bone Club

Renal expression of parvalbumin is critical for NaCl handling and response to diuretics

majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes

Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach

Genetic Screening of ZNF687 and PFN1 in a Paget’s Disease of Bone Cohort Indicates an Important Role for the Nuclear Localization Signal of ZNF687

Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone

Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology‐Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3‐Month Effects on Biomarkers of Bone Turnover

Suchergebnisse filtern